Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

CVS Health (CVS)

NYSE: CVS · Healthcare Plans · Woonsocket, RI

Our rating: Cautious

Call changed from Neutral to Cautious at $81.33, moderate conviction, November 5, 2026.

Breaks if: The Cautious call is invalidated if reported net margin recovers above 1.5% in either of the next two annual filings, signaling that the healthcare-benefits squeeze is genuinely easing and that amortization — not operating weakness — was the dominant drag on 2026 earnings. A stock move above $98 within twelve months, unaccompanied by that fundamental improvement, would also force a reassessment of what the market is crediting that the reported figures have not yet shown.

Key figures

Market value$103.4B
Revenue, last 12 months$420.6B
Net income, last 12 months$11.0B
Free cash flow, last 12 months$15.6B
Price to earnings9.4×
Free cash flow yield15.1%
Dividend yield3.3%
Operating margin3.6%
Return on equity14.4%
Beta to the S&P 5000.23
Volatility, annualized34.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$108.4B5.4%$1.68$3.9B
June 30, 2026$106.1B7.3%$2.31$5.7B
March 31, 2026$100.4B6.2%$2.30$3.4B
December 31, 2025$105.7B8.2%$2.32$2.6B
September 30, 2025$102.9B7.8%$-3.13$98M
June 30, 2025$98.9B8.4%$0.80$1.3B
March 31, 2025$94.6B7.0%$1.41$3.8B
December 31, 2024$97.7B4.2%$1.31$1.1B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 37 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.